AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval
Executive Summary
Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.
You may also be interested in...
AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025
Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.
AbbVie Says “V” Is For V-Shaped Recovery
The firm’s major product revenues bounced back from the pandemic-troubled second quarter, with Botox recovering as predicted.
AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials
AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports